“contraception in women with medical disorders”
DESCRIPTION
“CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”. NABEEL BONDAGJI, MD, FRCSC CONSULTANT PERINATOLOGIST KFSH&RC - JEDDAH. INTRODUCTION. Pregnancy spacing or control. Do no harm. Select appropriate method to the appropriate patient. Evidence based medicine with and against evidence. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/1.jpg)
NABEEL BONDAGJI, MD, NABEEL BONDAGJI, MD, FRCSCFRCSC
CONSULTANT PERINATOLOGISTCONSULTANT PERINATOLOGIST
KFSH&RC - JEDDAHKFSH&RC - JEDDAH
““CONTRACEPTION IN CONTRACEPTION IN WOMEN WITH WOMEN WITH
MEDICAL MEDICAL DISORDERS”DISORDERS”
![Page 2: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/2.jpg)
INTRODUCTIONINTRODUCTIONPregnancy spacing or Pregnancy spacing or control.control.Do no harm.Do no harm.Select appropriate method Select appropriate method to the appropriate patient.to the appropriate patient.Evidence based medicine Evidence based medicine with and against evidence.with and against evidence.Recommendation - strength Recommendation - strength of the recommendation.of the recommendation.
![Page 3: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/3.jpg)
Evaluation of the Evaluation of the Evidence Based On:Evidence Based On:
Evidence obtained from at least one properly Evidence obtained from at least one properly designed randomized controlled trial. designed randomized controlled trial.
Evidence obtained from well-designed Evidence obtained from well-designed controlled trials without randomization.controlled trials without randomization.
Evidence obtained from well-designed cohort Evidence obtained from well-designed cohort or case-control analytic studies, preferably or case-control analytic studies, preferably from more than one center or research from more than one center or research group.group.
..
![Page 4: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/4.jpg)
(Cont’d - Evaluation of (Cont’d - Evaluation of the Studies Based On:the Studies Based On:
Evidence obtained from multiple time series with or without the intervention.
Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.
.
![Page 5: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/5.jpg)
Evaluation of the Evaluation of the recommendation Based recommendation Based
On:On: Based on the highest level of evidence Based on the highest level of evidence found in the data, recommendations are found in the data, recommendations are provided and graded according to the provided and graded according to the following categories:following categories:
Level A -Level A - Recommendations are based on Recommendations are based on good and consistent scientific evidence.good and consistent scientific evidence.
Level B -Level B - Recommendations are based on Recommendations are based on limited or inconsistent scientific evidence.limited or inconsistent scientific evidence.
Level C -Level C - Recommendations are based Recommendations are based primarily on consensus and expert opinion.primarily on consensus and expert opinion.
![Page 6: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/6.jpg)
MEDICAL DISORDERSMEDICAL DISORDERS
D.M.D.M. HypertensionHypertension Venous thrombosisVenous thrombosis Migraine headacheMigraine headache Fibrocystic breast changesFibrocystic breast changes Fibro adenomaFibro adenoma Family history of breast CaFamily history of breast Ca
![Page 7: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/7.jpg)
( Cont’d) - MEDICAL ( Cont’d) - MEDICAL DISORDERSDISORDERS
HyperlipidemiaHyperlipidemia Sickle cell diseaseSickle cell disease SLESLE Patients who underwent Patients who underwent
valvular cardiac valvular cardiac replacementreplacement
![Page 8: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/8.jpg)
Patients on MedicationsPatients on Medications
Anticoagulant Anticoagulant therapytherapy
DrugsDrugs
AntibioticsAntibiotics
![Page 9: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/9.jpg)
D.M.D.M.Concerns:Concerns:CBCPCBCP
Theoretically impairment of Theoretically impairment of carbohydratecarbohydrate
progesterone component.progesterone component. Increased insulin and increased glucoseIncreased insulin and increased glucose Increase in the peripheral resistance to Increase in the peripheral resistance to
insulininsulin
Progesterone only pills (minipills)Progesterone only pills (minipills)
ImplantsImplants
DMPADMPASame Concern
![Page 10: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/10.jpg)
I.U.C.DI.U.C.D .. Immunity compromisedImmunity compromised Increased risk of infectionIncreased risk of infection
Mechanical barriers Mechanical barriers methodsmethods
Permanent MethodsPermanent MethodsNo major concerns
![Page 11: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/11.jpg)
Evidence in D. M.Evidence in D. M.The use of low does BCP did not alter The use of low does BCP did not alter the blood sugar content nor the blood sugar content nor accelerate the complications. accelerate the complications. Evidence Level IIEvidence Level II
No increased risk in CBCP user to No increased risk in CBCP user to developdevelop DM. DM.
Evidence Level IIEvidence Level II
Progesterone only pills- Progesterone only pills- No No conclusive evidence.conclusive evidence.
I.U.C.D. in well-controlled D.M. – No I.U.C.D. in well-controlled D.M. – No major difference in the risk of major difference in the risk of infection.infection.
Evidence Level IIEvidence Level II
![Page 12: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/12.jpg)
RecommendationsRecommendationsMechanical barriersMechanical barriers
Permanent sterilizationPermanent sterilization
Low dose CPCP in:Low dose CPCP in: Non-smokerNon-smoker 35 years old or younger35 years old or younger No hypertension, retinopathy, or No hypertension, retinopathy, or
vascular diseasevascular disease Level BLevel B
I.U.C.D.I.U.C.D. Level BLevel B
![Page 13: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/13.jpg)
HypertensionHypertensionConcerns:Concerns: CBCPCBCP
Increase in blood pressure 8/6 Increase in blood pressure 8/6 mmHgmmHg
Increased risk of vascular Increased risk of vascular events, increased three (3) fold events, increased three (3) fold in hypertensive on CBCPin hypertensive on CBCP
Increased risk of IHDIncreased risk of IHD
![Page 14: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/14.jpg)
Minipills Same concerns
I.U.C.D. No major concerns
Mechanical barriers No major concerns
(Cont’d) - (Cont’d) - HypertensionHypertension
![Page 15: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/15.jpg)
RecommendationsRecommendationsBCP
Women who have: Well-controlled BP
35 years old or younger
Non-smoker
No end organ damage Are allowed to have a trial of CBCP for a
few months if BP remains controlled to continue.
Level B
![Page 16: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/16.jpg)
(Cont’d) - (Cont’d) - RecommendationsRecommendations
I.U.C.D. No contraindication but no compelling
evidence of its safety (no major studies) Mechanical Barriers Permanent Sterilization
![Page 17: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/17.jpg)
Women with Fibrocystic Breast Women with Fibrocystic Breast Changes, Fibroderoma, Family Changes, Fibroderoma, Family
History of Breast CaHistory of Breast CaConcerns:Concerns:
CBCPCBCP Increased risk of breast Ca, small Increased risk of breast Ca, small
but not significantbut not significant Estrogen componentEstrogen component
Progesterone pill, implants DMPAProgesterone pill, implants DMPA No major concernsNo major concerns
I.U.C.D.I.U.C.D. No major concernsNo major concerns
![Page 18: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/18.jpg)
RecommendationsRecommendations CBCPCBCP
Women with fibroadenoma or benign Women with fibroadenoma or benign breast disease or family history of breast disease or family history of breast Ca can use CBbreast Ca can use CBCPCP safely. safely.
Level ALevel A
Progesterone only pillProgesterone only pill SafeSafe
I.U.C.D.I.U.C.D. SafeSafe
Barriers and permanent Barriers and permanent sterilizationsterilization SafeSafe
![Page 19: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/19.jpg)
Migraine HeadacheMigraine HeadacheConcerns:Concerns:
CBCPCBCP
In women with focal neurological signs four(4) fold In women with focal neurological signs four(4) fold increase in ischemic stroke.increase in ischemic stroke.
Risks increase in smokers thirty-four (34) fold. Risks increase in smokers thirty-four (34) fold. (Level II)(Level II)
Women with no focal neurological signs, no major Women with no focal neurological signs, no major increase in risk. increase in risk. (Level II) (Level II)
Progesterone containing BC method – same concern.Progesterone containing BC method – same concern.
I.U.C.D. – no major concern.I.U.C.D. – no major concern.
Mechanical barriers or permanent sterilization – no Mechanical barriers or permanent sterilization – no major concerns.major concerns.
![Page 20: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/20.jpg)
RecommendationsRecommendationsCBCP
Contraindicated in patients with migraine headache with neurological signs and can be used in patients without neurological signs, non-smoker, and younger than 35 years old.
To be discontinued if they develop
increase in headaches.
Level B
![Page 21: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/21.jpg)
(Cont’d) - (Cont’d) - RecommendationsRecommendations
I.U.C.D. Safe
Mechanical barriers or permanent sterilization Safe
![Page 22: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/22.jpg)
Patients who have Patients who have Undergone Cardiac Undergone Cardiac
Valvular ReplacementValvular ReplacementConcerns:Concerns:CBCPCBCP
Micro-emboli Estrogen effectMicro-emboli Estrogen effect I.U.C.D.I.U.C.D.
Risk of SBERisk of SBE
Barriers and permanent sterilizationBarriers and permanent sterilization No major concernsNo major concerns
![Page 23: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/23.jpg)
RecommendationsRecommendationsCBCPCBCP
ContraindicatedContraindicated
Level ALevel A
Progesterone only pillProgesterone only pill May be usedMay be used
Level BLevel B
I.U.C.D.I.U.C.D. No evidence to state that increased rate of SBE, No evidence to state that increased rate of SBE,
therefore, may be used therefore, may be used Level CLevel C
![Page 24: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/24.jpg)
Patients on Anti-Patients on Anti-Coagulants Coagulants
RecommendationsRecommendations CBCPCBCP
May be usedMay be used
Level BLevel B
Progesterone only pillProgesterone only pill May be usedMay be used
Level ALevel A
![Page 25: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/25.jpg)
(Cont’d) - Patients on Anti-(Cont’d) - Patients on Anti-Coagulants Coagulants
RecommendationsRecommendations
I.U.C.D. No major data
Can be used
Level C
![Page 26: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/26.jpg)
Women with Women with HyperlipidemiaHyperlipidemia
Concerns:Concerns:CBCPCBCP
Progesterone componentProgesterone component Increased LDL, decreased HDLIncreased LDL, decreased HDL Estrogen componentEstrogen component Decreased LDL, increased HDLDecreased LDL, increased HDL
Progesterone only pillProgesterone only pill Increased riskIncreased risk
I.U.C.D.I.U.C.D. No effectNo effect
Mechanical barriersMechanical barriers No effectNo effect
![Page 27: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/27.jpg)
RecommendationsRecommendations Women with controlled lipid profile may Women with controlled lipid profile may used CBCP.used CBCP. Women with uncontrolled lipid profile Women with uncontrolled lipid profile should not use CBCP.should not use CBCP.
Level CLevel C Progesterone containing agent, Progesterone containing agent, contraindicatedcontraindicated
Level BLevel B I.U.C.D., safeI.U.C.D., safe
Level ALevel A
![Page 28: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/28.jpg)
Women with SLEWomen with SLEConcerns:Concerns:
CBCPCBCP Increased flare up attacksIncreased flare up attacks Increased incidence of DVTIncreased incidence of DVT
Level IVLevel IV
Progesterone only pillProgesterone only pill No increased riskNo increased risk
Level IILevel II
![Page 29: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/29.jpg)
RecommendationsRecommendationsCBCPCBCP
To be avoidedTo be avoided Level BLevel B
ProgesteroneProgesterone only pill, DMPA, and implants are the only pill, DMPA, and implants are the methods of choice for SLE patients.methods of choice for SLE patients.
Level BLevel B
I.U.C.D.,I.U.C.D., barrier method, permanent sterilization. barrier method, permanent sterilization. SafeSafe
![Page 30: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/30.jpg)
Sickle Cell DiseaseSickle Cell DiseaseCBCPCBCP
Increased risk of vaso-occlusive Increased risk of vaso-occlusive
crisiscrisis
Level IIILevel III No major evidenceNo major evidence
DMPADMPA Decreased incidence of vaso-Decreased incidence of vaso-
occlusiveocclusive
crisiscrisis
Level IILevel II
![Page 31: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/31.jpg)
(Cont.’d) - Sickle Cell (Cont.’d) - Sickle Cell DiseaseDisease
I.U.C.D. No major concerns No data
Mechanical and permanent Safe
Level II
![Page 32: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/32.jpg)
RecommendationsRecommendations
CBCPCBCP To be avoidedTo be avoided
Level CLevel C
DMPADMPA To be usedTo be used
Level BLevel B
![Page 33: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/33.jpg)
Patients with History ofPatients with History of Venous ThrombosisVenous Thrombosis
Concerns:CBCP
Increased risk of venous thrombosis four (4) fold than non-users.
Mainly the estrogen component.
Progesterone only pills No major concerns
![Page 34: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/34.jpg)
(Cont’d) - Patients with (Cont’d) - Patients with History ofHistory of
Venous ThrombosisVenous ThrombosisConcerns:Mechanical barriers or
permanent sterilization. No major concerns
MPA and implants (hematoma)
I.U.C.D. menorrhagia in patient on anti-coagulant therapy
![Page 35: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/35.jpg)
RecommendationsRecommendationsCBCP
Contraindicated except during anti- coagulation therapy
Level A
Progesterone only pills Recommended in patients with VTE
Level A
DMPA implants should be avoided
Level A
![Page 36: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/36.jpg)
(Cont’d) - (Cont’d) - RecommendationsRecommendations
I.U.C.D. Can be used in patients who are off anti-
coagulation therapy May be used during anti-coagulation
therapy provided that patient does not develop significant menorrhagia
Mechanical barrier and permanent
sterilization methods allowed.
![Page 37: “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”](https://reader036.vdocuments.site/reader036/viewer/2022062321/56813fe5550346895daad02f/html5/thumbnails/37.jpg)
Thank Thank You..You..